Item 1.01. Entry Into A Material Definitive Agreement

On October 8, 2021, Regnum Corp ("Regnum") issued a convertible promissory note in the principal amount of US$1,500,000 to its principal shareholder, Phoenixus AG ("Phoenixus") to support clinical development and general expenses. The principal will bear interest at the rate of 3% per annum, payable on maturity or conversion. The note will mature 365 days following the date of issue, unless earlier repurchased or converted. Phoenixus has an option to convert the principal and interest into common shares of Regnum at US $0.40 per share, upon Regnum completing an equity financing of at least an additional US $5,000,000 in the aggregate.

The above description of the note is qualified in its entirety by reference to the form of such note attached as Exhibit 4.1 to this Current Report on Form 8-K.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosures set forth in Item 1.01 above are incorporated by reference into this Item 2.03.

Item 9.01. Financial Statements and Exhibits.





(c) Exhibits



Exhibit   Description
  4.1       Form of Convertible Promissory Note.
104       Cover Page Interactive Data File (formatted as Inline XBRL)





2

© Edgar Online, source Glimpses